SUMMARY:
- Impact Therapeutics is a biopharmaceutical company, announced that its ATR inhibitor IMP9064 has received the IND clearance from the US Food and Drug Administration (FDA) for the phase I/II clinical study, which will begin soon in the US. This will be the first in human study for the ATR inhibitor of Impact Therapeutics, representing a major leap of the company’s global development strategy for its synthetic lethality pipelines.
MPACT Therapeutics Announced ATR Inhibitor IMP9064 IND Clearance by USFDA.
IMPACT Therapeutics announced that its ATR inhibitor IMP9064 has received the IND clearance from the U.S. Food and Drug Administration (FDA) for the Phase I/II clinical study, which will begin soon in the U.S. This will be the first in human study for the ATR inhibitor of IMPACT Therapeutics, representing a major leap of the company’s global development strategy for its synthetic lethality pipelines.
This study is designed as a Phase I/II, dose escalation and expansion study, including individual arms to evaluate the safety, pharmacokinetics, and anti-tumor activities of IMP9064 as monotherapy and in combination with PARP inhibitor Senaparib in patients with advanced solid tumors.
IMP9064 is an ATR inhibitor discovered and developed by IMPACT Therapeutics, with worldwide intellectual property rights. In preclinical studies, IMP9064 was found to be a highly potent ATR inhibitor and is selective against other kinases. Additionally, IMP9064 has demonstrated high activities in several ATM-deficient cell lines and more active than reference compound in xenograft in vivo models, which could potentially lead to a wider therapeutic window, better tolerability in long-term administration as a single agent, and providing more flexibility in combination therapy. Senaparib, a PARP inhibitor developed by IMPACT Therapeutics, has been explored in several clinical studies worldwide. IMP9064 in combination with Senaparib will be evaluated in this clinical study to explore the combination therapy of an ATR inhibitor and a PARP inhibitor, which is highly anticipated in the DNA Damage Response (DDR) research field.
ATR is a synthetic lethality target of ATM mutations, which are commonly found in hematologic malignancies as well as a variety of solid tumors. ATR inhibitors have demonstrated proof-of-concept (POC) efficacy data in tumors harbored ATM mutations in previous clinical studies, and ATR is considered as one of the most promising synthetic lethality targets after PARP. Data from an ongoing ATR inhibitor clinical study presented at TRIPLE Conference 2021 showed that ATR inhibitor exhibits good efficacy as a monotherapy, but there is still significant room for improvement. This raised stronger interest to investigate combination of ATR inhibitor with other drugs. Among them, the combination of ATR inhibitor with PARP inhibitor is especially promising. In addition, the combination of ATR inhibitor with PARP inhibitor might overcome PARP inhibitor monotherapy resistance. As a company with both ATR inhibitor and PARP inhibitor in development, IMPACT Therapeutics is better positioned to study the combination therapy of ATR inhibitor with PARP inhibitor.
Combination therapy approach has been widely recognized as a major trend in the development of synthetic lethality-based therapeutics and targeted anticancer therapeutics to expand indications as well as to enhance anti-tumor activity. As a biopharmaceutical company dedicated to the discovery and development of novel therapeutics based on synthetic lethality, IMPACT Therapeutics has built extensive DNA Damage Response (DDR) pipelines including PARP, Wee1, ATR, and ATM inhibitors. IMPACT’s compounds were uniquely designed to have high activity and selectivity, which enables the company to target broader cancer indications and provide more opportunities for its in-house combination therapies.
Dr. Chih-Yi Hsieh, Senior Vice President and Chief Medical Officer said, “The pre-clinical data of IMP9064 has demonstrated its superiority among the same-class compounds. The clearance of this clinical program in the U.S. will enable us to validate the high potency, high selectivity, and robust anti-tumor activity of IMP9064 in the clinical study. IMPACT has formulated a differentiated clinical strategy for our ATR inhibitor which could advance the clinical development as efficient as possible, expand our synthetic lethality pipelines, and benefit more patients worldwide.”
What is ATR?
ATR is a DNA damage-signaling kinase activated at damaged replication forks, and ATR kinase inhibitors potentiate the cytotoxicity of DNA-damaging chemotherapies
What is the function of ATR?
ATR is a serine/threonine kinase and belongs to the phosphoinositide 3- kinase related protein kinases (PIKKs), particularly to ATM (ataxia telangiectasia mutated) subfamily. It functions to maintain genome integrity by stabilizing replication forks and by regulating cell cycle progression and DNA repair
Mechanism of Action (MOA):
MOA of ATR Inhibitors.
ATR inhibitors with radiotherapy
To repair radiation-induced DNA damage, cell cycle checkpoint activation is required, as it facilitates the time necessary for damaged-DNA reparations. Blocking ATR activity would not only impair DNA repair but would also block cell cycle checkpoint activation.
What is IND?
An Investigational New Drug Application (IND) is a request from a clinical study sponsor to obtain authorization from the Food and Drug Administration (FDA) to administer an investigational drug or biological product to humans. Clinical studies are often conducted to collect safety and effectiveness information in support of marketing applications for biologic and drug products. Unless exempted, the sponsor for a clinical study must obtain authorization from FDA for conducting the study by submitting an IND Application. Such authorization must be secured prior to interstate shipment and administration of any new drug or biological product that is not the subject of an approved New Drug Application or Biologics Product License Application.
About IMPACT Therapeutics
IMPACT Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. IMPACT Therapeutics has assembled one of the most comprehensive DNA damage response (DDR) global pipeline of novel drug candidates generated by in-house discovery efforts and is expanding to other novel synthetic lethality targets to broaden its pipeline. IMPACT pipeline products include PARP inhibitor (Senaparib/ IMP4297), Wee1 inhibitor (IMP7068), and other novel DDR pathway inhibitors. The lead clinical program, PARP inhibitor (Senaparib/ IMP4297), is in Phase II/III studies for ovarian cancer, prostate cancer, small cell lung cancer and other indications worldwide, including China. Senaparib’s preliminary clinical data demonstrated superior tolerability and wider therapeutic window compared with other PARPi. Phase I study of Wee1 inhibitor (IMP7068) is conducted globally. ATR Inhibitor IMP9064 has received IND Clearance by FDA to start clinical studies in the U.S. and Hedgehog pathway inhibitor (IMP5471) has received IND approval from NMPA to initiate clinical studies in China.
SOURCE: IMPACT therapeutics
For more Information: Sign-in Websites for Agrochemical & Pharmaceutical Databases:
Website: https://www.chemrobotics.com/ (Agrochemical Databases)
Website: https://chemroboticspharma.com/ (Pharmaceutical Databases)
